Somewhere Tom Scully is smiling
Executive Summary
UnitedHealth announces Sept. 1 that it is dropping AstraZeneca's proton pump inhibitor Nexium (esomeprazole) from the formularies of some of its commercial plans. United says the move does not affect its Medicare Part D plans, but AstraZeneca expects Nexium will be removed from additional United commercial formularies later this year. United says it made the decision in light of the availability of equally effective, less expensive options; esomeprazole is an isomer of AstraZeneca's Prilosec (omeprazole), which is available in over-the-counter and generic versions. AstraZeneca would not comment on the value of the United business, but says it is not revising revenue projections for Nexium for the remainder of 2006 and 2007. Nexium has been held up, by former CMS Administrator Tom Scully and others, as an example of a line extension that could be squeezed by the increasingly challenging reimbursement environment (1"The Pink Sheet" May 31, 2004, p. 28)...
You may also be interested in...
“Lifestyle” Drug Coverage Will Be Federal Policy Issue Under Medicare Rx
The debate over coverage of "lifestyle" drugs is likely to intensify as a federal policy issue once the Medicare prescription drug benefit takes effect in 2006
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.